Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 189

1.

Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients.

Yancey A, Harris MS, Egbelakin A, Gilbert J, Pisoni DB, Renbarger J.

Pediatr Blood Cancer. 2012 Jul 15;59(1):144-8. doi: 10.1002/pbc.24138. Epub 2012 Mar 19.

2.

Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.

van As JW, van den Berg H, van Dalen EC.

Cochrane Database Syst Rev. 2014 Jul 1;(7):CD009219. doi: 10.1002/14651858.CD009219.pub3. Review.

PMID:
24984156
3.

Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology Group.

Landier W, Knight K, Wong FL, Lee J, Thomas O, Kim H, Kreissman SG, Schmidt ML, Chen L, London WB, Gurney JG, Bhatia S.

J Clin Oncol. 2014 Feb 20;32(6):527-34. doi: 10.1200/JCO.2013.51.2038. Epub 2014 Jan 13.

4.

Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.

van As JW, van den Berg H, van Dalen EC.

Cochrane Database Syst Rev. 2012 May 16;(5):CD009219. doi: 10.1002/14651858.CD009219.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;(7):CD009219.

PMID:
22592737
5.

Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.

Bertolini P, Lassalle M, Mercier G, Raquin MA, Izzi G, Corradini N, Hartmann O.

J Pediatr Hematol Oncol. 2004 Oct;26(10):649-55.

PMID:
15454836
6.

Cisplatin-induced hearing loss: the need for a long-term evaluating system.

Yasui N, Adachi N, Kato M, Koh K, Asanuma S, Sakata H, Hanada R.

J Pediatr Hematol Oncol. 2014 May;36(4):e241-5. doi: 10.1097/MPH.0000000000000028.

PMID:
24072246
7.

Development and validation of a cisplatin dose-ototoxicity model.

Dille MF, Wilmington D, McMillan GP, Helt W, Fausti SA, Konrad-Martin D.

J Am Acad Audiol. 2012 Jul-Aug;23(7):510-21.

PMID:
22992258
8.

Incidence of platinum-induced ototoxicity in pediatric patients in Quebec.

Peleva E, Emami N, Alzahrani M, Bezdjian A, Gurberg J, Carret AS, Daniel SJ.

Pediatr Blood Cancer. 2014 Nov;61(11):2012-7. doi: 10.1002/pbc.25123. Epub 2014 Jun 29.

PMID:
24976616
9.

Ototoxicity in children treated for osteosarcoma.

Lewis MJ, DuBois SG, Fligor B, Li X, Goorin A, Grier HE.

Pediatr Blood Cancer. 2009 Mar;52(3):387-91. doi: 10.1002/pbc.21875.

PMID:
19061216
10.

Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma.

Bass JK, Huang J, Onar-Thomas A, Chang KW, Bhagat SP, Chintagumpala M, Bartels U, Gururangan S, Hassall T, Heath JA, McCowage G, Cohn RJ, Fisher MJ, Robinson G, Broniscer A, Gajjar A, Gurney JG.

Pediatr Blood Cancer. 2014 Apr;61(4):601-5. doi: 10.1002/pbc.24830. Epub 2013 Nov 1.

11.

Low incidence of ototoxicity with continuous infusion of cisplatin in the treatment of pediatric germ cell tumors.

Gupta AA, Capra M, Papaioannou V, Hall G, Maze R, Dix D, Weitzman S.

J Pediatr Hematol Oncol. 2006 Feb;28(2):91-4.

PMID:
16462581
12.

Cisplatin-induced ototoxicity in osteosarcoma patients: a report from the late effects surveillance system.

Stöhr W, Langer T, Kremers A, Bielack S, Lamprecht-Dinnesen A, Frey E, Beck JD; German Late Effects Working Group in the German Society of Pediatric Oncology and Hematology.

Cancer Invest. 2005;23(3):201-7.

PMID:
15945505
13.

Cisplatin-induced ototoxicity in pediatric solid tumors: the role of glutathione S-transferases and megalin genetic polymorphisms.

Choeyprasert W, Sawangpanich R, Lertsukprasert K, Udomsubpayakul U, Songdej D, Unurathapan U, Pakakasama S, Hongeng S.

J Pediatr Hematol Oncol. 2013 May;35(4):e138-43. doi: 10.1097/MPH.0b013e3182707fc5.

PMID:
23274376
14.

[The "Muenster classification" of high frequency hearing loss following cisplatin chemotherapy].

Schmidt CM, Bartholomäus E, Deuster D, Heinecke A, Dinnesen AG.

HNO. 2007 Apr;55(4):299-306. German.

PMID:
16437215
15.

Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens.

Dean JB, Hayashi SS, Albert CM, King AA, Karzon R, Hayashi RJ.

J Pediatr Hematol Oncol. 2008 Feb;30(2):130-4. doi: 10.1097/MPH.0b013e31815d1d83.

PMID:
18376265
16.

Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose.

Li Y, Womer RB, Silber JH.

Eur J Cancer. 2004 Nov;40(16):2445-51.

PMID:
15519518
17.

[Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients].

Biró K.

Magy Onkol. 2009 Sep;53(3):279-83. doi: 10.1556/MOnkol.53.2009.3.8. Hungarian.

18.

Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma.

Kushner BH, Budnick A, Kramer K, Modak S, Cheung NK.

Cancer. 2006 Jul 15;107(2):417-22.

19.

Hearing loss in Mexican children treated with cisplatin.

Castelán-Martínez OD, Jiménez-Méndez R, Rodríguez-Islas F, Fierro-Evans M, Vázquez-Gómez BE, Medina-Sansón A, Clark P, Carleton B, Ross C, Hildebrand C, Castañeda-Hernández G, Rivas-Ruiz R.

Int J Pediatr Otorhinolaryngol. 2014 Sep;78(9):1456-60. doi: 10.1016/j.ijporl.2014.06.007. Epub 2014 Jun 16.

PMID:
25037447
20.

Ototoxicity from cisplatin therapy in childhood cancer.

Coradini PP, Cigana L, Selistre SG, Rosito LS, Brunetto AL.

J Pediatr Hematol Oncol. 2007 Jun;29(6):355-60.

PMID:
17551394

Supplemental Content

Support Center